BBIO - BridgeBio Pharma, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 24.88

Open

$ 24.42

Bid

$ 0.00 x 0

Ask

$ 24.91 x 200

Day's Range

$ 24.33 - $ 24.95

52 Week Range

$ 12.75 - $ 44.32

Volume

1,049,219

Average Volume

Market Cap

4.05B

Beta (5Y Monthly)

$ 0.96

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-22-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-04-2023	03-31-2023	10-Q
5	02-23-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	02-25-2022	12-31-2021	10-K
10	11-04-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	02-25-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-11-2020	06-30-2020	10-Q
16	05-14-2020	03-31-2020	10-Q
17	03-03-2020	12-31-2019	10-K
18	11-08-2019	09-30-2019	10-Q
19	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Reported Sunday, BridgeBio Pharma Presente...
04/08/2024 06:50:03

- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional impr...

JP Morgan Maintains Overweight on BridgeBi...
03/20/2024 10:28:08

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $3...

Cantor Fitzgerald Maintains Overweight on ...
03/19/2024 12:35:55

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...

Cantor Fitzgerald Maintains Overweight on ...
03/11/2024 13:16:46

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...

BridgeBio Pharma Prices Public Offering Of...
03/06/2024 07:35:19

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expect...

Mizuho Maintains Buy on BridgeBio Pharma, ...
03/05/2024 13:09:04

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $60 to $53.

BridgeBio Pharma Announces Proposed Public...
03/04/2024 21:19:16

whats-going-on-with-bridgebio-pharma-stock-on-monday

What's Going On With BridgeBio Pharma Stoc...
03/04/2024 17:31:22

BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.

HC Wainwright & Co. Reiterates Buy on Brid...
03/04/2024 12:47:13

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $47 pr...

BridgeBio Pharma And Bayer Announce Europe...
03/04/2024 07:34:48

- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid c...

Recap: BridgeBio Pharma Q4 Earnings
02/22/2024 13:20:07

BridgeBio Pharma Q4 EPS $(0.96) Misses $(0...
02/22/2024 12:50:59

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(...

reliance-steel--aluminum-posts-upbeat-earnings-joins-jfrog-applovin-shake-shack-and-other-big-stocks-moving-higher-on-thursday

Reliance Steel & Aluminum Posts Upbeat Ear...
02/15/2024 15:23:41

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

BridgeBio, Kyowa Kirin Ink Partnership Wit...
02/07/2024 12:37:24

BridgeBio's affiliate, QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialize infigratinib ...

The FDA Has Bridgebio Pharma's New Drug Ap...
02/05/2024 12:34:22

AstraZeneca's Results From Japan Phase 3 T...
02/02/2024 09:51:40

BMO Capital Initiates Coverage On BridgeBi...
01/31/2024 11:02:25

BMO Capital analyst Kostas Biliouris initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Market Perform rating and a...

Invitae Partners with BridgeBio Pharma to ...
01/30/2024 12:07:59

Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBI...

HC Wainwright & Co. Maintains Buy on Bridg...
01/29/2024 11:37:23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price ...

Cantor Fitzgerald Reiterates Overweight on...
01/22/2024 13:46:58

Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $50 price ...